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Abstract Neurogenic inflammation mediated by peptidergic
sensory nerves has a crucial impact on the pathogenesis of
various joint diseases. Galanin is a regulatory sensory neuro-
peptide, which has been shown to attenuate neurogenic in-
flammation, modulate neutrophil activation, and be involved
in the development of adjuvant arthritis, but our current un-
derstanding about its targets and physiological importance is
incomplete. Among the receptors of galanin (GAL1–3), GAL3
has been found to be the most abundantly expressed in the
vasculature and on the surface of some immune cells.
However, since there are minimal in vivo data on the role of
GAL3 in joint diseases, we analyzed its involvement in differ-
ent inflammatory mechanisms of the K/BxN serum transfer-
model of autoimmune arthritis employing GAL3 gene-
deficient mice. After arthritis induction, GAL3 knockouts
demonstrated increased clinical disease severity and earlier
hindlimb edema than wild types. Vascular hyperpermeability
determined by in vivo fluorescence imaging was also elevated
compared to the wild-type controls. However, neutrophil ac-
cumulation detected by in vivo luminescence imaging or ar-
thritic mechanical hyperalgesia was not altered by the lack of
the GAL3 receptor. Our findings suggest that GAL3 has anti-
inflammatory properties in joints by inhibiting vascular
hyperpermeability and consequent edema formation.
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Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory autoim-
mune disease that primarily affects the synovial joints mani-
festing as pain, stiffness, and synovitis. Edema formation and
tenderness around the affected joints are characteristics of the
early phase of the disease which is associated with progres-
sive, irreversible degeneration and bone remodeling in later
stages. Despite the increasing number of novel drugs intro-
duced to treat RA (Smolen et al. 2007), long-term therapeutic
relief is still poor for most patients (Jones et al. 2003). As such,
there is still a great need for the identification of novel targets
and the subsequent development of efficacious and safe drugs.
While immunological aspects of the pathological mecha-
nisms of RA have been well described, components of the
nervous system have long been believed to be potential con-
tributors to immune-mediated disease conditions and recent
evidence has corroborated this assertion (Levine et al. 1985;
Bozic et al. 1996; Brogden et al. 2005; Kioussis and Pachnis
2009). The activation of the sensory nervous system triggers
the peripheral release of several peptide and non-peptide me-
diators. These can have both anti- or proinflammatory effects,
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thereby regulating the inflammatory microenvironment by al-
tering blood flow, vascular permeability, and leukocyte activ-
ity. This process, known as neurogenic inflammation (Holzer
1998), has been described clinically, where damage to the
central or peripheral nervous system can dramatically alter
the course of inflammatory diseases, such as RA (Thompson
and Bywaters 1962; Kim et al. 2012). It has also been shown
in preclinical models that an intact innervation is necessary for
the development of joint inflammation, suggesting a pivotal
role of pro-inflammatory neurotransmitters (McDougall et al.
1999; Kane et al. 2005; Stangenberg et al. 2014). In contrast,
however, the defunctionalization of peptidergic sensory affer-
ents can also lead to increased inflammation in several animal
models (Helyes et al. 2004; Borbely et al. 2015). Thus, the
role of neurogenically released peptide mediators in joints can
be somewhat divergent with some neuropeptides being clearly
pro-inflammatory (e.g., substance P) (McDougall et al. 1994),
while others have anti-inflammatory properties (e.g., pituitary
adenylate cyclase-activating polypeptide or endomorphin-1)
(McDougall et al. 2004; Botz et al. 2014). The role of numer-
ous other peptide mediators and their receptors including the
galanin family in RA has yet to be examined.
Galanin is a sensory neuropeptide with a length of 30 (29 in
rodents) amino acids that is ubiquitously expressed in both the
central and peripheral nervous systems and has numerous bi-
ological and physiological functions. Three galanin receptors
(GAL1–3) have been identified, which are all G-protein-
coupled receptors (GPCR) showing distinct differences re-
garding their tissue expression pattern (Lang et al. 2015).
Both GAL1 and GAL2 are present in abundance throughout
the central nervous system, whereas GAL3 expression is much
more restricted to the hippocampus (Mennicken et al. 2002).
In non-neural tissues, GAL2 and GAL3 are predominantly
expressed (Santic et al. 2007). The functional coupling and
signal transduction pathways of the three galanin receptors are
substantially different, giving rise to the great variety of
galanin-mediated effects. While it was shown that GAL1
mainly signals via Gi/o-type G proteins and GAL2-mediated
effects involve multiple classes of G proteins, the signaling
pathways of GAL3 are not well understood (Lang et al. 2015).
Galanin has been shown to be upregulated following nerve
damage (Ch’ng et al. 1985; Skofitsch and Jacobowitz 1985;
Hokfelt et al. 1987) and has been implicated in nociception
(Liu and Hokfelt 2002; Lang et al. 2015), as both galanin and
its receptors are expressed in dorsal root ganglia and in the
spinal dorsal horn (Landry et al. 2005). Galanin knockout
mice exhibit increased sensitivity to mechanical and thermal
stimuli, whereas galanin-overexpressing mice show an in-
creased thermonociceptive threshold (Blakeman et al. 2001;
Holmes et al. 2003). Furthermore, the galanin peptide family
is undoubtedly involved in the regulation of inflammatory
processes with the galanin system being upregulated in the
central and peripheral nervous systems in response to
inflammation (Ji et al. 1995). Galanin has been shown to have
anti-inflammatory and most importantly anti-edema effects in
animal models of inflammation (Lang and Kofler 2011).
GAL3 was found to be active in the dermal microvasculature,
as treatment with its selective small molecule antagonist
SNAP 37889 dose-dependently blocked the anti-edema effect
of galanin (Schmidhuber et al. 2009). Furthermore, galanin
gene-deficient mice lack neurogenic inflammatory responses
and have impaired neutrophil recruitment into inflamed tis-
sues (Schmidhuber et al. 2008). According to recent data,
GAL2 but not GAL1 is expressed on both human and murine
neutrophils, whereas galanin and GAL3 are expressed on mu-
rine neutrophils only. Additionally, it has been reported that
galanin can act as a modulator of cytokine-induced neutrophil
activation (Locker et al. 2015). Galanin itself has been impli-
cated in arthritis as an endogenous regulatory mediator.
Several studies reported a change in galanin mRNA levels,
galanin-like immunoreactivity, and galanin peptide levels, re-
spectively, in the rat dorsal horn of the spinal cord, dorsal root
ganglia, and joint tissue after experimentally induced adjuvant
arthritis (Hope et al. 1994; Calza et al. 1998; Calza et al. 2000;
Qinyang et al. 2004). Hence, the galanin system poses a novel
target for alternative treatment stategies for RA; however, no
studies have been conducted identifying the relevant galanin
receptor subtype.
The K/BxN serum-transfer model of autoimmune arthritis
(Kouskoff et al. 1996; Korganow et al. 1999) mimics numer-
ous aspects of RA in humans. The model produces a transient,
but profuse polyarthritis following systemic administration of
exogenous antibodies (anti-glucose phosphate isomerase)
with the involvement of neutrophils (but not of T/B cells).
This arthritis model also has a distinct neurogenic component
(Korganow et al. 1999; Botz et al. 2014; Stangenberg et al.
2014; Borbely et al. 2015).
Since galanin participates in the pathogenesis of arthritis
and because GAL3 is expressed on murine neutrophils and
has been shown to influence vascular components of inflam-
matory processes, we hypothesize that GAL3 is involved in
inflammatory joint diseases. Therefore, the aim of the present
study was to elucidate if GAL3 plays a role in the K/BxN
serum transfer model of autoimmune arthritis.
Materials and Methods
Experimental Animals
Experiments were conducted using 12–14-week-old male
GAL3 gene-deficient (GAL3
−/−) mice and age-matched wild-
type (GAL3
+/+) controls (body weight 25–30 g). GAL3
−/−
(LEXKO-230) mice were obtained from the European
Mouse Mutant Archive. The mice were generated by homol-
ogous recombination with targeting both coding exons. The
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mouse line was backcrossed onto a C57BL/6 lineage for at
least seven additional generations and was maintained on this
background. The successful knockout of the GAL3 gene has
been established recently (Brunner et al. 2014). All animals
were GAL3 genotyped before the experiments. Animals were
bred and kept in the Laboratory Animal House of the
Department of Pharmacology and Pharmacotherapy of the
University of Pécs, at 24–25 °C ambient temperature, and
provided with standard rodent chow and water ad libitum
under 12-h light-dark cycles.
The K/BxN Serum-Transfer Induced Inflammatory
Arthritis
K/BxN mice express a transgenic T cell receptor and the MHC
class II allele Ag7. This leads to the production of autoanti-
bodies against the enzyme glucose-6-phosphate isomerase
and consequent development of progressive polyarthritis.
Transfer of K/BxN serum into mice elicits a robust, albeit
transient, polyarthritis. This serum transfer model mimics pre-
dominantly the effector phase of RA and depends mainly on
mast cells and neutrophils, but not on lymphocytes (Monach et
al. 2008). The sera of transgene-positive (K/BxN) and negative
(BxN) mice were harvested, pooled, and stored at −80 °C as
described earlier (Korganow et al. 1999; Jakus et al. 2009).
Arthritis was induced by a single intraperitoneal (i.p.) injection
of 300μl of the arthritogenic (K/BxN) or control (BxN) serum.
Evaluation of Disease Severity and Hindpaw Edema
Arthritis severity was evaluated daily until 13 days post
serum injection by semiquantitative scoring between 0 and
10 based on two key signs of inflammation: edema and
hyperemia. A score of ≤0.5 represented a normal hindlimb,
and 10 refers to the most severe level of joint inflammation
with accompanying gait abnormality. Hindlimb edema was
also monitored repeatedly (on days 0, 2, 4, 6, 8, and 11 post
serum injection) by plethysmometry (Ugo Basile, Comerio,
Italy).
Assessment of Mechanonociception and Joint Function
The mechanical hyperalgesia of the hindpaw was measured
every second day by dynamic plantar esthesiometry
(Ugo Basile). Mechanonociceptive threshold was expressed
as percentage of pretreatment controls. Grasping ability was
tested repeatedly (on days 0, 2, 4, and 6 post serum injection)
by placing the mice on a horizontal wire-grid, which was then
turned over and maintained in this position for 30 s or until the
animal fell (Jakus et al. 2009).
In vivo Fluorescence Imaging of Plasma Leakage
On days 0, 1, and 5, post serum injection mice received a
retroorbital injection of the fluorescence contrast agent
indocyanine-green (0.5 mg/kg body weight) dissolved in
5 % w/v Kolliphor HS 15 solution (Sigma-Aldrich)
(Kirchherr et al. 2009) under ketamine-xylazine anesthesia
(ketamine 100 mg/kg; xylazine 5 mg/kg body weight i.p.). It
has been demonstrated that this micellar fluorescent contrast
agent enables sensitive noninvasive detection of microvascu-
lar extravasation (Botz et al. 2014). The underlying principle
of this technique is that the labeled micelles serve as
nanoprobes that can leave the microvasculature of inflamed
tissues, but not the intact vessels due to their size (∼10 nm).
This results in retention and buildup of fluorophore in the
inflamed tissue, culminating in increased fluorescence that
correlates with the severity of the disease (Kenne and
Lindbom 2011). Animals were imaged 20 min post-injection
using the IVIS Lumina II system (Perkin-Elmer, Waltham,
MA, USA). Imaging parameters were set to the following:
auto acquisition time, F/Stop = 1, Binning = 2. The excitation
and emission filters were 745/800 nm. Data were analyzed
using the Living Image® software; regions of interests
(ROIs) were drawn around the hind limbs. A calibrated unit
of fluorescence, the radiant efficiency ([photons/s/cm2/sr]/
[μW/cm2]) originating from the ROIs was used for further
analysis.
In vivo Bioluminescence Imaging of Neutrophil
Myeloperoxidase Activity
Luminol (5-amino-2,3-dihydro-1,4-phthalazine-dione) is a
chemiluminescent reactive oxygen species sensor, which in
vivo requires both the superoxide-production of nicotinamide
adenine dinucleotide phosphate oxidase and the activity of the
myeloperoxidase (MPO) enzyme. The MPO-dependent na-
ture of luminol makes it a suitable chemiluminescent tracer
to image the activity of this enzyme, and thereby the function-
ing of neutrophils in vivo, as most of the MPO-activity is
localized in the phagosomes of those cells during inflamma-
tion (Gross et al. 2009; Tseng and Kung 2012). On days 0, 1,
and 5, post serum injection mice received an i.p. injection of
20 mg/ml PBS-based solution of sodium-luminol (Sigma-
Aldrich) at a dose of 150 mg/kg, and were imaged 10 min
post-injection using the IVIS Lumina II. Acquisition time was
60 s, F/stop = 1, Binning = 8. ROIs were applied as previously
described and luminescence was expressed as total radiance
(total photon flux/s).
Histology
Joint samples were harvested on day 14 following eutha-
nasia by sodium pentobarbital (100 mg/kg i.p.). Ankle
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joints were fixed in 40 mg/ml buffered formaldehyde,
dehydrated using ethanol and xylol, and finally decalcified
with EDTA. The samples were embedded in paraffin,
sectioned (3–5 μm), and stained with fast green and
safranine O.
Dynamic Mass Redistribution Assay
Murine polymorphonuclear neutrophils were isolated
from the bone marrow as described previously (Locker
et al. 2015). Cells were resuspended in Hank’s Balanced
Salt Solution containing magnesium and calcium [HBSS
(+/+)] (Gibco), diluted in HBSS (+/+) containing 20 mM
HEPES (Gibco), and then seeded onto EnSpire LFC-384
well plates coated with fibronectin (Perkin-Elmer) at a
density to achieve a confluent monolayer (60,000–80,
000 cells/well). The plates were centrifuged for 10 s at
1000g and equilibrated for 1 h in the EnSpire machine
(Perkin-Elmer). First, the pretreatment baseline was ac-
quired by measuring 4 repeats (30 s each) followed by
the addition of compounds [KC (the murine homolog of
IL-8) (1 pM–100 nM), KC (1 pM–100 nM) with 10 μM
galanin, KC (1 pM–100 nM) with 1 μM galanin, and KC
(1 pM–100 nM) with 0.1 μM galanin]. The plate was
measured for 20 repeats. Each experiment was carried
out in triplicate, and the mean was used to generate the
dynamic mass redistribution (DMR) traces. The half max-
imal effective concentration (EC50) of KC was then
calculated.
Expression Analysis
Expression profiles of galanin and its receptors was performed
in 16–24-week-old male GAL3
−/− and GAL3
+/+ mice as de-
scribed previously (Brunner et al. 2014). Briefly, mice were
euthanized by CO2 overdose and cervical dislocation. Tissue
was dissected and immediately snap-frozen in liquid nitrogen.
RNA isolation was performed with TRI Reagent (Molecular
Research Center, Inc.) according to the manufacturer’s in-
structions. Synthesis of cDNAwas performed by use of ran-
dom hexamer primers and Maxima reverse transcriptase
(Thermo Scientific) according to the manufacturer’s instruc-
tions. Expression profiles of galanin and GAL1–3 were quan-
tified by quantitative real-time PCR using B-R SYBR Green
SuperMix for iQ (Quanta BioSciences, Inc.) and iCycler iQ
real-time PCR detection system (Bio-Rad Laboratories).
Primer sequences and cycling conditions are taken from
Brunner et al. (2014).
Statistical Analysis
Results are expressed as mean ± SEM. Statistical evalua-
tion was performed by Graphpad Prism®. Functional data
were analyzed by two-way ANOVA + Tukey’s multiple
comparison test, grasping ability results by logrank test,
imaging, DMR assay, and expression analysis results by
Student’s unpaired t test. p values below 0.05 were
considered significant.
Results
More Severe Arthritis Progression and Accelerated
Edema Formation in GAL3
−/− Mice Joint inflammation oc-
curred in GAL3
+/+ and GAL3
−/−mice with similar kinetics and
peaks at day 7, but GAL3
−/− mice showed a more severe
arthritis phenotype compared to wild types (peak difference
observed from day 3 to 5 with p < 0.0001) (Fig. 1a). The
plethysmometric determination of the hindpaw volume re-
vealed an earlier peak of edema formation in GAL3
−/− mice
(GAL3
−/− day 4 at 65 %; GAL3
+/+ day 6 at 50 %), and a more
robust plasma extravasation on days 2 to 6 in GAL3
−/− mice
compared to GAL3
+/+ wild types (peak differences on day 4
p < 0.0001 and day 6 p = 0.0238) (Fig. 1b).
GAL3 Deficiency Does not Influence Nociception orMotor
Performance in the Arthritis Model As RA is known to
affect nociception and motor performance, we tested whether
GAL3 is involved in pain perception. A considerable and sim-
ilar mechanonociceptive threshold drop of about 40–50 %
was observed in both the GAL3
−/− and GAL3
+/+ mice on day
8 of the experiment (Fig. 1c), indicating increased pain in both
groups. Grasping ability also decreased steadily following se-
rum injection. This reached a peak by day 6 as almost all K/
BxN serum-treated GAL3
−/− and GAL3
+/+ animals became
unable to maintain their position on the grid for the duration
of the test period (Fig. 1d).
Increased Early-Phase Arthritic Vascular Hyperpermeability
in GAL3 Knockouts Plasma leakage after arthritis induc-
tion was assessed by in vivo fluorescence imaging.
Pretreatment control fluorescence was comparable in
GAL3
−/− and GAL3
+/+ mice. The degree of plasma ex-
travasation increased sharply upon K/BxN serum trans-
fer in both groups, peaking 24 h after arthritis induction
in the hyperacute phase of the disease. GAL3
−/− mice
exhibited 40 % greater vascular hyperpermeability
(p < 0.01) compared to wild types. This significant dif-
ference in plasma leakage resolved by day 5, albeit the
overall degree of vessel hyperpermeability remained
similar in the two groups (Fig. 2a, b).
Similar MPO-Activity and Joint Damage in Arthritic
GAL3
−/− Mice As neutrophil recruitment is a characteristic
of the K/BxN model of autoimmune arthritis, we aimed to
evaluate the involvement of GAL3 in activating neutrophils
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using in vivo bioluminescence imaging. Baseline luminol bio-
luminescence was negligible in both groups. Following K/
BxN serum-transfer, the MPO-derived ROS production in-
creased dramatically in both GAL3
−/− and GAL3
+/+ animals,
reaching a peak on day 1. Neutrophil ROS production de-
creased considerably by day 5, indicating that the disease
was already in transition from a neutrophil-dominated acute
phase into the chronic macrophage-mediated stage. However,
MPO-activity did not differ significantly between knockouts
and wild types on day 1 or 5 (Fig. 2c, d). Histological samples
were harvested 14 days after serum transfer revealed a similar
phenomenon. The synovial lining was thickened, and the nor-
mally adipocyte-rich periarticular connective tissue was re-
placed with a dense fibroblastic scar tissue, with limited in-
flammatory cell infiltration. No remarkable difference was
observed in these respects between the study groups, in agree-
ment with the absent functional difference at this stage of the
disease (Fig. 3).
Sensibilization of Neutrophils by Galanin Is GAL3
Independent
Since no difference in neutrophil infiltration could be
observed between wild-type and knockout animals, we
tested if the recently reported modulation of neutrophil
activation by galanin is GAL3 dependent (Locker et al.
2015). We found that in polymorphonuclear neutrophils
isolated from the bone marrow (BM-PMNs) of GAL3
−/−
mice, galanin co-treatment resulted in a similar dose-
Fig. 1 GAL3-deficiency leads to increased edema and inflammation
without affecting nociception or motor functions. a Change of disease
severity in wild-type (GAL3
+/+) and gene-deficient (GAL3
−/−) mice. b
Hindlimb edema measured by plethysmometry. c Arthritic mechanical
hyperalgesia measured by plantar esthesiometry. d Motor impairment
measured by wire grid grip test and plotted as a survival curve. Two-
wayANOVA+Tukey’s multiple comparison test, survival curve: logrank
test. Controls: n = 6–7, arthritic groups: n = 9–12. *p < 0.05, **p < 0.01,
****p < 0.0001 vs. respective wild type
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dependent shift of the DMR and consequently a similar
modulation of the EC50 of KC, the murine homolog of
IL-8, compared to wild-type mice (Fig. 4). This finding
is in agreement with the in vivo data presented here,
showing that GAL3 is not affecting neutrophil function.
Expression Profiles of the Galanin System Are Not
Affected by the GAL3 Knockout
Since compensatory upregulation of galanin and the other
galanin receptors in the GAL3
−/− mice could potentially
Fig. 2 GAL3 deficiency results in increased and early vascular
hyperpermebility in arthritis, without directly affecting neutrophil ROS
production. a Representative in vivo fluorescence images highlighting
indocyanine-green extravasation. b Quantification of normalized fluores-
cence in the hind paws representing the degree of vascular leakiness
(n = 5–6). c Quantification of normalized luminescence in the hind limbs
showingMPO-derived ROS-production of neutrophils (controls: n = 6–7,
arthritic groups: n = 9–12). d Representative in vivo luminescence im-
ages. Student’s unpaired t test, **p < 0.01 vs. respective wild type
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influence our findings, we analyzed expression levels of
galanin and its receptors in the spleen, lung, kidney, liver,
and testes of GAL3
−/− and GAL3
+/+ mice. We found that
deltaCt values of galanin system genes compared to the
housekeeping gene HPRT were similar in GAL3
−/− and
GAL3
+/+ animals, indicating no compensatory mechanisms
in peripheral tissues of GAL3-deficient mice (Table 1).
Discussion
Our results suggest a modest involvement of GAL3 receptor
signaling in neurogenic inflammatory arthritis by decreasing
microvascular leakage and consequent edema formation.
The vasoregulatory role of peripherally released galanin
has been investigated previously where it was found to be able
to inhibit histamine-induced edema formation in the skin
(Jancso et al. 2000). Later results also revealed that GAL2
and GAL3, but not GAL1, are expressed in the skin and the
anti-edema effect of galanin is presumably mediated through
these receptors present on perivascular neural, but not endo-
thelial or smooth muscle tissues (Schmidhuber et al. 2007).
Consistent with our finding in K/BxN-induced arthritis, it was
reported that inhibition of GAL3 signaling with SNAP 37889
also resulted in elevated edema formation (Schmidhuber et al.
2009). Our results suggest that GAL3-agonism is an endoge-
nous protective mechanism in immune-mediated arthritis
driven by neurogenic factors. Previously, it was demonstrated
that galanin immunoreactivity increases in the dorsal root gan-
glion during experimental arthritis (Calza et al. 2000). In ad-
juvant arthritis of the rat, others found a decrease in galanin
immunoreactivity in the sciatic nerve and macrophage-like
cells, whereas it was found to be elevated, e.g., in fibroblasts,
osteoblasts, and the polymorphonuclear lineage cells of the
bone marrow (Qinyang et al. 2004). However, the observed
Fig. 3 Representative microphotographs of the joint samples of GAL3
+/+
(a, b, e, f) and GAL3
−/− (c, d, g, h) mice taken on day 14 after arthritis
induction. The adipocyte-rich periarticular connective tissue of the con-
trol groups (a, c, e, g) (illustrated by the frame) was replaced with a dense
fibroblastic scar tissue, with a limited presence of inflammatory cells in
the arthritic groups (b, d, f, h). No difference was observed in these
respects between the study groups [fast green and safranin O staining,
×100 (a–d) and ×200 (e–h) magnification]
Fig. 4 Comparison of the relative EC50 of BM-PMNs from wild-type
C57BL/6 mice (Locker et al. 2015) and BM-PMNs from GAL3 gene-
deficient animals. The cells were treated with KC, the murine homo-
log of IL-8, in the presence of a fixed concentration of galanin. Data
were normalized to KC treatment alone, which was set to 100 %.
Data were analyzed with Student’s t test for unpaired and paired
comparisons (with Welch correction), respectively. *p < 0.05 vs.
respective KC alone (n = 8–9)
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difference in our model is not necessarily galanin-mediated, as
galanin-like peptide (GALP) is also able to activate the GAL3
receptor (Lang et al. 2015). Furthermore, it has been shown
recently that the novel neuropeptide spexin is a more potent
agonist of GAL3 than galanin itself (Kim et al. 2014).
Unfortunately, it has not been shown so far if spexin is able
to activate GAL3 in vivo or if it is expressed inmurine joints or
neutrophils. Therefore, it is not possible to state which of these
three peptides is responsible for the observed GAL3-mediated
effects in K/BxN induced arthritis.
We did not observe any difference in neutrophil MPO-ac-
tivity, suggesting that GAL3-deficiency in vivo may not influ-
ence the function of these immune cells. Indeed, recent results
show that GAL3 is not expressed in mature human blood
neutrophils unlike murine bone marrow neutrophils.
Whether this discrepancy reflects a species-difference or the
difference between the sites of collection (peripheral blood vs.
bone marrow) remains to be addressed. Galanin was also
found to modulate the sensitivity of neutrophils isolated from
the murine bone marrow towards KC, the murine homolog of
IL-8 (Locker et al. 2015). We show here that this modulation
is independent of the GAL3 genotype, supporting the finding
that neutrophil activation is not dependent on GAL3 expres-
sion, at least not in K/BxN-induced murine arthritis.
Interestingly, another study found that in a mouse model of
acute pancreatitis, GAL3 antagonism by the selective
nonpeptide antagonist SNAP 37889 ameliorated disease se-
verity (Barreto et al. 2011). However, more recently, SNAP
37889 has been found to be cytotoxic in a variety of cell types,
including, but not limited to, myeloid lineages. Since this ef-
fect is GAL3-independent (Koller et al. 2015), results obtained
with SNAP 37889 have to be interpreted with care.
The lack of effect of GAL3 gene-deletion on mechanical
hyperalgesia and accompanying loss of grasping function is
supported by earlier findings implicating GAL1 and GAL2 but
not GAL3 in nociceptive transmission. Since GAL3 shows
only a very limited expression in the nervous system, this
observation is in agreement with earlier results (Landry et al.
2005; Lang et al. 2015).
In this study, we also found no evidence that compensatory
mechanisms of the galanin system occur in peripheral tissues
of GAL3
−/− animals. Previously, Brunner and coworkers also
reported no change in expression levels of the galanin system
in different brain regions of these mice (Brunner et al. 2014).
Therefore, compensatory mechanisms of the galanin system
in GAL3
−/− mice can be excluded. However, we did not elu-
cidate whether expression levels of galanin signaling elements
are altered in the present mouse model and which signaling
pathways are involved in the observed GAL3-mediated ef-
fects. Besides, signaling properties of GAL3 are still poorly
defined. One explanation for this gap in knowledge is the lack
of cell lines which endogenously express GAL3 only.
Additionally, overexpression of GAL3 in different cell lines
leads to the translation of the protein mainly as intracellular
high molecular weight protein aggregates while omitting
functional activation by exogenous galanin (Robinson et al.
2013; Lang et al. 2015). In vivo, GAL3 might interact with
other GPCRs or arrestins etc. which stabilize GAL3 on the
membrane. However, to our knowledge, there are no data
available supporting this theory.
In conclusion, our findings suggest that GAL3 is a potential
target through which galanin can reduce joint swelling, but not
nociception. Since the K/BxN serum-transfer model depends
on an intact innervation of the hindlimb and involves early
neurogenic vasodilation (Binstadt et al. 2006; Stangenberg et
al. 2014), activation of the GAL3 receptor may offset and limit
the extent of neurogenic inflammation in joints. However,
GAL3 is not a sine qua non of the inflammatory cascade due
to the functional redundancy of sensory neuropeptides on a
functional level, and also because GAL3-activation is
Table 1 Expression levels of galanin system genes displayed as deltaCt values compared to the housekeeping gene HPRT in GAL3
+/+ and GAL3
−/−
mice. Data are represented as mean ± SEM, n = 2–4
Gene GAL GAL1 GAL2 GAL3
Tissue Genotype ΔCt p value ΔCt p value ΔCt p value ΔCt p value
Spleen GAL3
+/+ 4.0 ± 1.5 0.347 10.0 ± 2.1 0.459 14.8 ± 0.5 0.058 12.0 ± 0.5 n.a.
GAL3
−/− 5.8 ± 0.9 12.0 ± 1.4 16.5 ± 0.5 n.d.
Lung GAL3
+/+ 5.4 ± 0.2 0.180 11.3 ± 0.8 0.999 12.8 ± 0.1 0.644 10.3 ± 0.5 n.a.
GAL3
−/− 5.9 ± 0.3 11.3 ± 1.0 12.3 ± 0.5 n.d.
Kidney GAL3
+/+ 13.2 ± 0.4 0.412 14.4 ± 1.0 0.723 11.1 ± 0.3 0.568 9.4 ± 0.7 n.a.
GAL3
−/− 12.6 ± 0.6 13.9 ± 0.4 10.7 ± 0.5 n.d.
Testes GAL3
+/+ 5.5 ± 0.5 0.486 n.d. n.a. 7.5 ± 0.4 0.609 13.4 ± 0.2 n.a.
GAL3
−/− 5.9 ± 0.3 n.d. 7.7 ± 0.1 n.d.
Liver GAL3
+/+ 16.7 ± 0.9 0.860 n.d. n.a. 15.2 ± 0.6 0.357 15.6 ± 0.7 n.a.
GAL3
−/− 17.0 ± 1.3 n.d. 16.5 ± 1.5 n.d.
n.d. not detectable, n.a. not applicable
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responsible for only a fraction of the beneficial effects of
galaninergic mediators. The anti-inflammatory effect of
galanin peptides is mediated via multiple receptors, and
GAL3-activation does play a role in the attenuation of the
vascular component of nerve-driven inflammation. Thus, af-
finity towards GAL3 would be a desirable attribute for the
development of effective anti-edema galanin-analogs.
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